Writing
Pharmaceutical company Elli Lilly will start selling 2.5 milligram vials of its weight-loss drug tirzepatide (Zepbound) for up to $399 (303.46 euros) a month starting Tuesday, which is equivalent to a discount of around 50% compared to the price of the same product in self-injectables.
In this way, patients with prescriptions for tirzepatide will be able to directly purchase ampoules for daily use for 30 days through the Web page from the multinational. In addition, Lilly will also offer the possibility of obtaining a more potent dose of 5 milligrams for 549 dollars (491.44 euros) per month.
Lilly will also offer the possibility of obtaining a more potent dose of 5 milligrams for 549 dollars (491.44 euros) per month.
Tirzepatide has so far been administered with an auto-injector pen, but with the vial system, users will have to refill the syringes themselves. This method will allow Lilly to accelerate commercialization of tirzepatide, since the manufacture of the self-injectable was hindering the capture of market share against other competitors, such as Novo Nordisk’s Ozempic.
The company’s executive vice president, Patrik Jonssonsaid the move is part of Lilly’s plan to increase supplies of tirzepatide and Mounjaro, a similar diabetes treatment, in response to high demand for these products.
